NDA 212102 · Ucb INC
Fintepla
Fenfluramine Hydrochloride · Oral
Priority reviewOrphanLast checked: Nov 20, 2026Latest source record: May 22, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Jun 25, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
26
12 Phase 3, 4 recruiting
FAERS reports
5,252
4,328 serious, 135 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION FINTEPLA can cause valvular heart disease and pulmonary arterial hypertension [see Warnings and Precautions (5.1) ]. Echocardiogram assessments are required before, during, and after treatment with FINTEPLA. The benefits versus the risks of initiating or continuing FINTEPLA must be considered, based on echocardiogram findings [see Dosage and Administration (2.1 , 2.6 ) and Warnings and Precautions (5.1) ]. Because of the risks of valvular heart disease and pulmonary arterial hypertension, FINTEPLA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the FINTEPLA REMS [see Warnings and Precautions (5.2) ]. WARNING: VALVULAR HEART DISEASE and PULMONARY ARTERIAL HYPERTENSION See full prescribing information for complete boxed warning. FINTEPLA can cause valvular heart...
What it is approved for
From the label in effect Oct 22, 2026.
FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older. FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients 2 years of age and older. ( 1 )
Mechanism: The precise mechanism by which fenfluramine exerts its therapeutic effects in the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome is unknown. Fenfluramine and the metabolite, norfenfluramine, exhibit agonist activity at serotonin 5-HT2 receptors. There is an association between serotonergic drugs with 5-HT2B receptor agonist activity, including fenfluramine and norfenfluramine, and valvular heart disease and pulmonary arterial hypertension.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 25, 2022 Supplement 3 · Efficacy · priority review OrphanLabelLetter
- Jun 25, 2020 Original approval · Type 3 - New Dosage Form · priority review OrphanLetterLabelReview
1 products under this application
- FINTEPLA · FENFLURAMINE HYDROCHLORIDE EQ 2.2MG BASE/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fenfluramine" as an intervention, any sponsor and status, largest first.
- A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut SyndromePivotal-lookingCompleted
Zogenix, Inc.Industry
NCT03936777 · 412 participants · Start Apr 22, 2019 · Primary completion May 8, 2025
Drug: ZX008 (Fenfluramine Hydrochloride) · For: Dravet Syndrome; Lennox Gastaut Syndrome; Epileptic Encephalopathy
Sites: Tucson, Arizona; Los Angeles, California; San Diego, California · 71 sites in all
- An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet SyndromePivotal-lookingCompleted
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
NCT02823145 · 375 participants · Start Jun 8, 2016 · Primary completion Jan 27, 2023
Drug: ZX008 (Fenfluramine Hydrochloride) · For: Dravet Syndrome
Sites: Phoenix, Arizona; Tucson, Arizona; Orange, California · 67 sites in all
- A Study to Investigate the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) as an Adjunctive Therapy in Children and Adults With Lennox-Gastaut SyndromePivotal-lookingCompleted
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
NCT03355209 · 296 participants · Start Nov 27, 2017 · Primary completion May 23, 2024
Drug: ZX008 0.2 or 0.8 mg/kg/day; Matching Placebo · For: Lennox Gastaut Syndrome
Sites: Tucson, Arizona; Los Angeles, California; San Francisco, California · 72 sites in all
- A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet SyndromePivotal-lookingCompleted
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
NCT02682927 · 262 participants · Start Jan 15, 2016 · Primary completion Jul 29, 2020
Drug: ZX008 (Fenfluramine Hydrochloride); Matching Placebo · For: Dravet Syndrome; Seizure Disorder
Sites: Phoenix, Arizona; Tucson, Arizona; San Diego, California · 55 sites in all
- A Phase 3 Study of Fenfluramine Hydrochloride in Rett SyndromePivotal-lookingRecruiting
NCT07503444 · 200 participants (planned) · Start Jul 14, 2026 · Primary completion Feb 6, 2029
Drug: fenfluramine hydrochloride · For: Rett Syndrome
Sites: Little Rock, Arkansas; Miami, Florida; Orlando, Florida · 46 sites in all
- A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Pivotal-lookingActive, not recruiting
Zogenix, Inc.Industry
NCT05064878 · 87 participants · Start Mar 8, 2022 · Primary completion Nov 8, 2027
Drug: Fenfluramine; Placebo · For: CDKL5 Deficiency Disorder; Generalized Tonic Clonic Seizure; Epileptic Spasm and 1 more
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 46 sites in all
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.Industry
NCT02926898 · 87 participants · Start Jan 27, 2017 · Primary completion Jun 5, 2018
Drug: ZX008 (Fenfluramine Hydrochloride); Matching Placebo · For: Dravet Syndrome
Sites: San Francisco, California; Aurora, Colorado; Chicago, Illinois · 28 sites in all
- Fenfluramine and CognitionCompleted
University of OxfordAcademic, hospital or other
NCT05026398 · 56 participants · Start Apr 12, 2021 · Primary completion Jun 22, 2022
Drug: Fenfluramine · For: Cognitive Function
Sites: Oxford, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- seizure2,298
- drug ineffective795
- tricuspid valve incompetence722
- off label use610
- decreased appetite593
- somnolence502
- weight decreased491
- mitral valve incompetence424
- fatigue372
- diarrhoea334
- generalised tonic-clonic seizure290
- hospitalisation276
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 11 |
| 2020 | 44 |
| 2021 | 451 |
| 2022 | 743 |
| 2023 | 602 |
| 2024 | 910 |
| 2025 | 1,357 |
| 2026 | 1,095 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Fintepla (Fenfluramine HCl)
2024 spending
$40.9M
Beneficiaries
292
2,456 claims
Per beneficiary
$140,018
$55.08 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $225,197 |
| 2021 | $1,760,999 |
| 2022 | $7,233,074 |
| 2023 | $17,962,601 |
| 2024 | $40,885,327 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Pharmacotherapy for obesity.
Ioannides-Demos LL, Proietto J, McNeil JJ · Drugs 2005 · Meta-Analysis, Review
- Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial.
Knupp KG, Scheffer IE, Ceulemans B, et al. · JAMA Neurol 2022 · Multicenter Study, Randomized Controlled Trial
- Comparative efficacy and safety of stiripentol, cannabidiol and fenfluramine as first-line add-on therapies for seizures in Dravet syndrome: A network meta-analysis.
Guerrini R, Chiron C, Vandame D, et al. · Epilepsia Open 2024 · Systematic Review, Comparative Study
- Fenfluramine in the treatment of Dravet syndrome: Results of a third randomized, placebo-controlled clinical trial.
Sullivan J, Lagae L, Cross JH, et al. · Epilepsia 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force.
Tomson T, Battino D, Bromley R, et al. · Epileptic Disord 2022 · Systematic Review
- Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L, Sullivan J, Knupp K, et al. · Lancet 2019 · Comparative Study, Randomized Controlled Trial
Sponsor: UCB
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.